Selected Start-Ups (11/00)
Executive Summary
In Vivo summarizes the technologies of several recently founded companies: CryoCor Inc.will use cryonic ablation technology to treat cardiac arrhythmias. Expert Biomed Inc.is engaged in the search for therapeutics for Alzheimer's disease as well as new cancer diagnostics. Hypnion Inc. will use specialized screening and functional genomics services to discover novel drugs for sleep disorders and circadian rhythm abnormalities. France's Nautilus Biotech will use its proprietary analytical and gene transfer vector technology to support the drug discovery efforts of its customers. Neurogenetics Inc. aims to develop small molecule therapeutics to halt the progression of Alzheimer's disease and other neurodegenerative disorders. Robinson Medical Inc. will commercialize technology for the non-invasive continuous, real-time measurement of blood flow during cardiac surgery.
You may also be interested in...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.